The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma

Eur J Ophthalmol. Nov-Dec 2006;16(6):816-23. doi: 10.1177/112067210601600606.

Abstract

Purpose: To compare the efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% when added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma.

Design: A prospective, double-masked, randomized, active-controlled, parallel comparison.

Methods: Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily. Patients returned to clinic at Week 4 (Visit 3) for a safety visit and Week 12 (Visit 4) for an efficacy visit. At Visits 2 and 4 the intraocular pressure (IOP) was measured at 08:00, 12:00, and 16:00 hours.

Results: Ninety-seven patients on brinzolamide had a baseline diurnal IOP of 21.5+/-2.2 mmHg and 95 on timolol maleate had 21.3+/-2.5 mmHg, each added to travoprost. The diurnal mean IOP at Week 12 was 18.1+/-2.7 mmHg for brinzolamide and 18.1+/-3.0 mmHg for timolol maleate (p=0.96). There was no statistical difference found between treatment groups in the absolute level of pressure, or in the reduction in IOP from baseline, at each time point or for the diurnal curve (p>0.05). There was no significant difference for any adverse event between groups (p>0.05), with the most common side effect being conjunctival hyperemia in 15/97 (16%) brinzolamide and 6/95 (6%) timolol treated patients (p=0.06).

Conclusions: This study showed that brinzolamide provides similar safety and efficacy compared to timolol maleate when added to travoprost.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / adverse effects
  • Carbonic Anhydrase Inhibitors / administration & dosage*
  • Carbonic Anhydrase Inhibitors / adverse effects
  • Circadian Rhythm
  • Cloprostenol / administration & dosage
  • Cloprostenol / adverse effects
  • Cloprostenol / analogs & derivatives*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Glaucoma, Open-Angle / drug therapy*
  • Glaucoma, Open-Angle / physiopathology
  • Humans
  • Intraocular Pressure / drug effects
  • Intraocular Pressure / physiology
  • Male
  • Middle Aged
  • Ocular Hypertension / drug therapy
  • Ocular Hypertension / physiopathology
  • Prospective Studies
  • Sulfonamides / administration & dosage*
  • Sulfonamides / adverse effects
  • Thiazines / administration & dosage*
  • Thiazines / adverse effects
  • Timolol / administration & dosage*
  • Timolol / adverse effects
  • Tonometry, Ocular
  • Travoprost
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Carbonic Anhydrase Inhibitors
  • Sulfonamides
  • Thiazines
  • Cloprostenol
  • Timolol
  • brinzolamide
  • Travoprost